BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...exercised an exclusive option to ex-U.S. development and commercialization rights to then-clinical stem cell therapy Cx601...
BioCentury | Apr 29, 2019
Company News

April 29 Quick Takes: Takeda, Emendo, ViiV, Zynquista, Benlysta and more

...autism symptoms as measured by the Childhood Autism Rating Scales-2. Elizabeth S. Eaton, Staff Writer Alofisel, darvadstrocel (Cx601) darolutamide...
BioCentury | Mar 30, 2018
Clinical News

EU approval for alofisel to treat perianal fistulas

...N.V. (Euronext:TIG; NASDAQ:TIG), Leuven, Belgium Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Alofisel darvadstrocel (Cx601...
BioCentury | Jan 12, 2018
Company News

Takeda acquiring TiGenix for €520M

...announced. Takeda called the deal a “natural extension” of the companies’ partnership for Alofisel darvadstrocel (Cx601...
...Leuven, Belgium Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Gene/Cell therapy, Autoimmune, Musculoskeletal Jaime De Leon Alofisel Cx601 darvadstrocel Takeda...
BioCentury | Jan 5, 2018
Company News

Takeda acquiring TiGenix for €520M

...NASDAQ. Takeda called the deal a “natural extension” of the companies’ partnership for Alofisel darvadstrocel (Cx601...
...companies expect an approval decision this half (see BioCentury Extra, Dec. 15, 2017) . Jaime De Leon Alofisel Cx601 darvadstrocel Takeda...
BioCentury | Dec 22, 2017
Clinical News

CHMP backs TiGenix's Alofisel for Crohn's

...EMA's CHMP recommended approval of Alofisel darvadstrocel (Cx601) from TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) and Takeda Pharmaceutical...
...Leuven, Belgium Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Alofisel darvadstrocel (Cx601) Business: Autoimmune Allison Johnson Alofisel Cx601 darvadstrocel Takeda...
BioCentury | Dec 22, 2017
Clinical News

TiGenix to discontinue cardiovascular pipeline

...focus on candidates derived from its expanded adipose-derived stem cell (eASC) platform, including Alofisel darvadstrocel (Cx601...
...in vitro Indication: Treat acute myocardial infarction (MI) Endpoint: NA Status: Development discontinued Milestone: NA Allison Johnson AlloCSC-01 Alofisel Cx601 Cx611 Takeda...
BioCentury | Dec 15, 2017
Company News

CHMP recommends basket of therapies

...EMA's CHMP recommended approval of a host of therapies, including Alofisel darvadstrocel (Cx601) to treat Crohn's...
BioCentury | Jul 5, 2017
Clinical News

TiGenix starts Phase III ADMIRE-CD II trial of Cx601

...TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) began the Phase III ADMIRE-CD II trial of Cx601 to treat complex...
...at week 52 as stipulated in the original 2015 SPA (see BioCentury, March 13 ). Cx601...
...BioCentury, March 14, 2016 ). TiGenix granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive rights to Cx601...
BioCentury | Mar 9, 2017
Clinical News

Cx601 regulatory update

...FDA agreed to a shortened Phase III trial design for Cx601 to treat perianal fistulas in...
...expects to begin the Phase III trial this half and submit a BLA by 1H20. Cx601...
...Euronext:TIG; NASDAQ:TIG), Leuven, Belgium Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Cx601 Business: Autoimmune Alicia Parker Cx601 Takeda...
Items per page:
1 - 10 of 31